Work

RNA Therapeutic Agents as a New Generation of Drugs for the Treatment of Cardiovascular Diseases

Year: 2025

Type: article

Abstract: RNA therapeutic agents represent a novel and promising class of drugs aimed at preventing and treating various diseases, including cardiovascular pathologies. These agents enable temporary regulation of target gene expression, opening new possibilities for therapy. Depending on the approach, RNA-based drugs can replace, supplement, correct, or suppress gene expression. The main classes of RNA therapy include antisense oligonucleotides (ASOs), microRNAs (miRNAs), small interfering RNAs (siRNAs), RNA aptamers, and messenger RNAs (mRNAs). This article discusses existing challenges, such as drug delivery to target organs, as well as the advantages of RNA therapy, including cost-effectiveness, simplicity of production, and the ability to target hard-to-treat diseases. Additionally, the mechanisms of action of various RNA-based drugs and their impact on gene expression are thoroughly reviewed. Particular attention is given to clinical trials and the efficacy of drugs that have already received regulatory approval.

Source: Bulletin of Science and Practice

DOI: 10.33619/2414-2948/119/17

Authors: K. Aitbaev, I. Murkamilov, А. Yusupov, Z. Raimzhanov, Zh. Murkamilova, F. Yusupov, T. Yusupova, O. Zakirov, K. Khabibullaev, I. Abdibaliev

Institutions: Kyrgyz State Medical Academy, Osh State University, Kyrgyz-Russian Slavic University named after B.N. Yeltsin

Language: English

Topic: RNA Interference and Gene Delivery

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W4415225710

FWCI:

Cites:

Cited by:

Related to: